Skip to content

Unlocking the full therapeutic potential of psychedelics

approach 1

A new type of biotech company

approach 2

Credentialed science with viable commercial applications

approach 3

Meeting the challenges of mainstreaming a new class of medicines

2013 - 2016

Assessment of Drug Class Clinical Feasibility and Translational Challenges

Founded in 2013, Eleusis is the first clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics through conventional clinical development and regulatory approval.

In 2015 and 2016, Eleusis conducted two clinical trials of lysergic acid diethylamide (LSD). These trials focused on establishing a basic framework for the future clinical development of psychedelics in the context of Alzheimer’s disease and depression.

Phase I Trials:

Low Dose LSD

Moderate Dose LSD

2017 - 2020

Development of Translational Solutions

Eleusis identified translational challenges to the clinical development of psychedelics in the context of psychiatry and as anti-inflammatory medicines. In psychiatric application, these challenges included the incidence of adverse effects (i.e. anxiety, nausea), prolonged treatment duration, and the intrapatient variability of dose response. Beyond Psychiatry, the primary challenge identified was to minimize the perceptual effects of psychedelics while maximizing the immunomodulatory and neuroprotective activity.

2020 - 2025

Clinical Development and New Drug Development

Eleusis is now embarking on a full clinical development program of ELE-Psilo as a treatment for major depressive disorder. In parallel, Eleusis is continuing its drug discovery and development programs beyond psychiatry in an effort to fully unlock the therapeutic potential of psychedelics.

Eleusis is a life science company based in London and New York, dedicated to transforming psychedelics into medicines

General & Media Inqueries

Careers Opportunities


New York